Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.

Kalpana Ramanna MaliMadhavi Eerike Gerard Marshall RajDebasis BisoiRekha PriyadarshiniGandham RaviLeo Francis ChaliserrySiddharam S Janti

Published in: Irish journal of medical science (2022)

Evidence from clinical studies showed that Molnupiravir caused significant reduction in the risk of hospitalization or death in high-risk mild COVID-19 patients. Molnupiravir was also found to be well tolerated and safe without any major adverse events on short-term use. For confirmative use of this drug in mild-to-moderate COVID-19 disease, further studies are required in vaccinated COVID-19 patients and against emerging variants.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
copy number
gene expression
adverse drug
dna methylation
electronic health record